Cytokinetics (CYTK) free cash flow

Free cash flow · fiscal 2025
-$534.82M

Cytokinetics (CYTK) generated free cash flow of -$534.82M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$399.80M. Figures as of 18 Nov 2026, 12:36 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
-$534.82M
Highest on record
$35.39Mfiscal 2016
Lowest on record
-$534.82Mfiscal 2025
Fiscal years on record
172009–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Cytokinetics free cash flow, in more detail

Across the 17 fiscal years on record (2009–2025), the highest was $35.39M in fiscal 2016 and the lowest -$534.82M in fiscal 2025.

History · 17 fiscal years

Free cash flow by fiscal year

Cytokinetics free cash flow, year by year

Cytokinetics (CYTK) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025-$534.82M—
2024-$399.80M—
2023-$415.75M—
2022-$310.85M—
2021-$191.39M—
2020-$2.11M—
2019-$93.53M—
2018-$102.10M—
2017-$104.64M 395.7% down
2016$35.39M 718.9% up
2015$4.32M—
2014-$45.95M—
2013-$8.26M—
2012-$33.56M—
2011-$46.04M—
2010-$45.32M 676.2% down
2009$7.87M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of Cytokinetics and comparable companies
CompanyFree cash flowFiscal year
Alkermes ALKS$480.33M2025
PACS Group PACS$155.07M2025
Kiniksa Pharmaceuticals International KNSA$136.42M2025
Cytokinetics CYTK-$534.82M2025
ABIVAX ABVX-€161.27M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on CYTK

Cytokinetics, figure by figure

Cytokinetics (CYTK) overview: price, valuation and scorecardAll health care companies by market value

Cytokinetics free cash flow: questions and answers

What is Cytokinetics's free cash flow?

Cytokinetics (CYTK) generated free cash flow of -$534.82M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$399.80M.

What are the highest and lowest free cash flow figures on record for Cytokinetics?

Across the 17 fiscal years on record (2009–2025), the highest was $35.39M in fiscal 2016 and the lowest -$534.82M in fiscal 2025.

How is Cytokinetics's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Cytokinetics it is on record here for 17 fiscal years, 2009 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Cytokinetics (CYTK) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/CYTK/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.